Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

Hepatitis C virus infection in children and adolescents

“…Ever‐evolving treatment regimens are available that reliably achieve a >95% “real‐world” cure rate for all HCV genotypes 6. Efficacy has also been demonstrated in historically difficult to treat populations, such as patients with pretreatment cirrhosis, renal disease, patients previously exposed to antiviral therapy, prior null responders, those with HIV co‐infection, and patients following liver transplantation 95, 96, 97, 98, 99…”

Untitled

“…Another clinical trial with grazoprevir (formerly MK-5172, a protease inhibitor) and elbasvir (an NS5A inhibitor) for treatment of genotype 1 HCV infection in patients with chronic kidney disease is currently ongoing. 65 With the introduction of ledipasvir and sofosbuvir, the infection cure rates have improved to more than 90% with possible exclusion of interferon and ribavirin. 60 After excellent results were shown with DAAs in naïve, uncomplicated patients,66 clinical trials are being conducted to evaluate these agents in difficult to treat patients, such as those previously treated for HCV infection (Table 3), 66 patients with cirrhosis, liver transplant recipients, patients coinfected with HIV, chronic kidney disease patients, and patients with multidrug resistant viral infection.Limited evidence exists regarding the use of these agents in patients with chronic kidney disease, including renal transplant recipients.…”

Elbasvir/Grazoprevir

“…1 The doses used for treating hepatitis C infections in dose-ranging studies included elbasvir 20 mg and 50 mg and grazoprevir 100 mg, both administered orally once daily. 12,13 The doses mainly used in phase 3 clinical trials were elbasvir 50 mg and grazoprevir 100 mg in a fixed-dose combination tablet taken once daily. 4,5,6,7,27 No dosage adjustment is necessary for patients with any degree of renal impairment, including patients requiring hemodialysis, or for patients with mild hepatic impairment.…”